ClinicalTrials.gg

Program

Crovalimab

Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Anemia, Sickle Cell · Antiphospholipid Syndrome · Guillain-Barre Syndrome, led by Hoffmann-La Roche.

Furthest: phase 3, since Jun 3, 202010 company-led studies, 5 open or runningNext primary completion: Apr 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche105 open or runningphase 3since Jun 3, 2020Nov 1, 2016Apr 18, 2027phase 3 · NCT04432584

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2016First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT03157635 · 59 enrolled · France, Germany, Hungary and more
  2. Jun 3, 20202 phase 3 studies in Hemoglobinuria, ParoxysmalNCT04434092, NCT04432584
  3. Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalNCT04654468 · 51 enrolled · China
  4. Apr 23, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04861259 · 83 enrolled · United States, Belgium, Brazil and more
  5. Jun 2, 2021Phase 1 study in Anemia, Sickle CellNCT04912869 · 30 enrolled · United States, Brazil, France and more
  6. Jul 6, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04958265 · 41 enrolled · United States, Belgium, Brazil and more
  7. Sep 20, 2021Phase 2 study in Anemia, Sickle CellNCT05075824 · 95 enrolled · United States, Brazil, France and more
  8. Aug 8, 2022Phase 3 study in Guillain-Barre SyndromeNCT05494619
  9. Sep 11, 2025Phase 2 study in Antiphospholipid SyndromeNCT07172022

Ahead

  1. Apr 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04432584

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07172022Antiphospholipid Syndrome2WithdrawnMar 11, 20300
NCT05494619Guillain-Barre Syndrome3WithdrawnMar 19, 20260
NCT05075824Anemia, Sickle Cell · United States, Brazil, France and more2CompletedJun 11, 202595
NCT04958265Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more3Active, not recruitingJul 4, 202541
NCT04912869Anemia, Sickle Cell · United States, Brazil, France and more1CompletedDec 23, 202430
NCT04861259Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more3Active, not recruitingOct 9, 202583
NCT04654468Hemoglobinuria, Paroxysmal · China3Active, not recruitingFeb 10, 202251
NCT04434092Hemoglobinuria, Paroxysmal · Argentina, Brazil, China and more3Active, not recruitingNov 16, 2022210
NCT04432584Hemoglobinuria, Paroxysmal · United States, Belgium, Brazil and more3Active, not recruitingApr 18, 2027190
NCT03157635Hemoglobinuria, Paroxysmal · France, Germany, Hungary and more2CompletedAug 13, 202659

How it is read

Names in the registry

  • “Crovalimab”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.